UK markets close in 8 hours 16 minutes

Biogen Inc. (BIIB.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
5,951.00-32.60 (-0.54%)
At close: 2:46PM CDT
Sign in to post a message.
  • B
    BIIB's sell off should be expected and should continue given that Aduhelm FAILED.... to improve cognition in their P3 trials; an alarming 40% of patients experienced painful brain swelling, and the cost of treatment is extremely expensive. For example, Dr Constantine Lyketsos, the director of the Memory and Alzheimer's Treatment Center at Johns Hopkins said that Aduhelm treatment costs are about "$100,000" a year, per patient due to safety monitoring and MRIs. Add it all up, it's not surprising that most global HC Payers are not giving the green light to Aduhelm...Again, BIIB's Aduhelm launch problems were caused by the FDA, for approving a treatment that was overwhelmingly rejected by the expert ADCOM panel.
  • K
    So much for all those 400 and 450 price targets last month...Perfect example of why analysts don't know any more than you do. They're just overpaid researchers doing the same thing that any joe shmo on the street can can, and getting the same info thats available anywhere on the web.
  • B
    Could Biogen plummet to around $200 or so if Congress and the FDA decide to pull Aduhelm from the market ? Time will tell.
  • B
    Bite em
    SAVA in the drivers seat.
  • A
    Buy SAVA and thank me later ;)
  • n
    Nobody is going to pay $65,000 for the snake oil Alzheimer drug period.
  • w
    Biogen drug removes plaque, a best marker for Alzheimer disease at least now, with some effect on slowing down on memory deterioration. If I I’m in early dementia and have that amount of money to spare, I will certainly take it. If Medicare pays some, even better. Without trying, the memory goes down quickly. I invest in biib, sava, avxl, anvi, because I may need down the road. Support them now and reap the benefits later.
  • S
    With the exception of MRNA most of my drug stocks have been under attack even the good dividend ones such as ABBV, AMGN. I don’t get it!
  • l
    ( is truly one of the best stock advice newsletters out there! Their daily emails give me all the information I need to trade more wisely each day. I rely heavily on their watchlists and recommend all traders should do the same!
  • B
    Thanks for another successful transaction of $25, 000. I'm so glad trading in your platform
    Stephanie A William
  • H
    Time to switch over to SAVA
  • K
    People don't even want this dangerous drug for free...Doesn't that tell you something???? Get out while you can and buy the real winner, SAVA!
  • O
    Added 534 shares. Youre basically getting the stock without the Alzheimer's drug at this price, and the Alzheimer’s drug could become over 60% of its profits by the end of next year🤣🤣🤣🤣
  • O
    $BIIB breaking out. Looking so STRONG. I'm loving this! Let's get to $340 by Friday. Let this news marinate
  • O
    $BIIB GOINGGGGGG!! Most stocks are OVERBOUGHT. Traders running away from the market and ignoring one of the FEW stocks in the country that's OVERSOLD. See you at $400+🤷‍♂️📚
  • Y
    imagine buying biogen lmao
  • C
    The Ship is taking on water, so it's time to head toward the life boats.
  • s
    If a drug has severe side effects why would the developer give it for free. Because people have been scared of this drug .. once a few hundred people start and no major issues the news will spread
  • s
    I think what people are not realizing is the Aduhelm and Donanemab are not intended for the AZ community of 6 million. But for the ageing population 55 plus who have plaque but no signs of cognitive decline just yet. That market is 50 million strong.

    Think of it like Prep for HIV! Or Rogaine for people who have not yet lost hair. It’s a preventative approach that works not curative.

    That’s a far bigger market worldwide than a cure for AZ!!

    When will the market realize that???? When the trials further elucidate the effectiveness as a prophylactic treatment !

    This will then see 100 billion sales world wide.

    2025-2027 Biogen will be a 150 billion company